Combination therapy – mycolab.ai

Proteomic study of medicinal mushroom extracts reveals antitumor mechanisms in an advanced colon cancer animal model via ribosomal biogenesis, translation, and metabolic pathways

mycolabadmin

Scientists studied how special medicinal mushroom extracts can fight advanced colon cancer in mice. They found that a blend called Agarikon Plus, especially when combined with a common chemotherapy drug, significantly improved survival rates and slowed tumor growth. By analyzing all the proteins in tumor tissues, they discovered the mushroom extracts work by disrupting the cancer cells’ ability to make proteins they need to survive and grow. This research suggests mushroom-based treatments could become important new weapons in the fight against advanced colorectal cancer.

Editorial: Raising the bar: advancing therapeutic strategies for fighting communicable and noncommunicable diseases

mycolabadmin

Scientists are developing new ways to fight dangerous infections caused by bacteria, viruses, and drug-resistant pathogens. Recent discoveries include safer uses of existing drugs, better dosing strategies tailored to individual patients, and effective combination therapies that reduce antibiotic resistance. These advances represent important progress in treating serious infectious diseases like COVID-19, tuberculosis, and bacterial infections.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers studied how Bunium persicum essential oil and two of its active components work together with the antifungal drug fluconazole to fight resistant Candida yeast infections. They found that cuminaldehyde, one of the oil’s main components, was particularly effective when combined with fluconazole and could trigger yeast cell death. These natural compounds could offer a promising new approach to treating fungal infections that have become resistant to standard medications.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and dangerous, especially for people with weakened immune systems, and many fungi are developing resistance to current medications. Doctors and researchers are developing new treatment strategies, including combining multiple drugs together and using advanced technologies to deliver medicines more effectively to infected areas. Natural compounds from plants and new biotechnology tools like genetic engineering and nanoparticles show promising results for fighting drug-resistant fungal infections.

Leveraging synthetic genetic array screening to identify therapeutic targets and inhibitors for combatting azole resistance in Candida glabrata

mycolabadmin

Candida glabrata is a dangerous fungus causing serious infections that is becoming resistant to antifungal drugs. Researchers used a genetic screening technique to find genes that interact with drug resistance mutations and identified methotrexate (a drug already used for arthritis) as a potential partner for fluconazole treatment. When combined, these drugs work better together against resistant strains of the fungus, offering hope for treating these stubborn infections.

Antifungal Activity of Selected Naphthoquinones and Their Synergistic Combination with Amphotericin B Against Cryptococcus neoformans H99

mycolabadmin

Researchers tested five compounds called naphthoquinones for their ability to fight a dangerous fungal infection called cryptococcosis. They found that one compound called 2-MNQ works especially well when combined with the standard antifungal drug amphotericin B, making the treatment more effective. This discovery could lead to better treatments for people with weakened immune systems who are vulnerable to this infection.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers studied how an essential oil from black cumin seeds (Bunium persicum) and two of its key active components could work together with the antifungal drug fluconazole to fight Candida albicans infections, including drug-resistant strains. Using laboratory tests and computer modeling, they found that cuminaldehyde, one of the main components, was particularly effective when combined with fluconazole, killing yeast cells through multiple mechanisms. This suggests that natural plant compounds could be valuable partners with conventional antifungal medications to overcome drug resistance.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers tested how Bunium persicum essential oil and its components work alongside the antifungal drug fluconazole against Candida albicans infections. Cuminaldehyde, a major component of the oil, showed the strongest effects when combined with fluconazole, making infection-causing cells die faster than each substance alone. This combination approach could help overcome drug-resistant fungal infections and offers a promising natural alternative to synthetic drugs alone.

HIV protease inhibitors restore amphotericin B activity against Candida

mycolabadmin

Researchers discovered that HIV protease inhibitors, medications commonly used to treat HIV, can significantly enhance the effectiveness of amphotericin B, a powerful antifungal drug. When combined, these medications work synergistically to kill the dangerous fungus Candida auris, reduce its ability to form protective biofilms, and lower infection levels. This finding suggests a promising new treatment strategy for multidrug-resistant fungal infections that currently pose a serious global health threat.

Research Topic: Combination therapy